H.E.L.P. Apheresis vs INUSpheresis: Which Blood Filtration Therapy?

If you are researching therapeutic apheresis — particularly for post-COVID recovery, microclot reduction, or chronic inflammatory conditions — you have likely encountered two names: H.E.L.P. Apheresis and INUSpheresis. Both are blood filtration therapies available at German clinics and increasingly discussed in integrative medicine circles. Both are presented as treatments for similar conditions. And the confusion between them is understandable, because neither system’s marketing clearly explains how they differ.

Here is what the evidence shows, how each system actually works at a technical level, and how I think about recommending one versus the other.

At a Glance

How H.E.L.P. Apheresis Works

H.E.L.P. Apheresis (Heparin-induced Extracorporeal LDL Precipitation) was developed in the 1980s by B. Braun Melsungen AG for the treatment of severe familial hypercholesterolemia. It has since found broader applications in cardiovascular disease, microcirculatory disorders, and more recently, post-COVID syndrome.

The technical process:

1. Blood withdrawal: Blood is drawn from a peripheral vein and separated into plasma and cellular components using a standard plasma separator.
2. Heparin addition: The plasma fraction is mixed with heparin at a specific concentration and acidic pH (approximately pH 5.12). At this pH, heparin forms insoluble complexes with LDL cholesterol, Lp(a), fibrinogen, and C-reactive protein (CRP). These precipitate out of solution.
3. Filtration: The precipitate is removed by passage through a polycarbonate filter, trapping the heparin-lipoprotein-fibrinogen complexes.
4. Bicarbonate dialysis: Excess heparin is removed from the filtered plasma through a dialysis step using bicarbonate buffer. This also restores physiological pH.
5. Reconstitution: The cleaned plasma is recombined with the cellular components and returned to the patient.

What it removes (and by how much per session):

• LDL cholesterol: 55-70% reduction
• Lipoprotein(a): 55-70% reduction
• Fibrinogen: 55-65% reduction
• C-reactive protein: 50-60% reduction
• Various inflammatory mediators co-precipitated with the fibrinogen-lipoprotein complex

The cardiovascular evidence base:

H.E.L.P. Apheresis has the strongest evidence base of any apheresis system for cardiovascular indications. The HELP-LDL-Apheresis Multicentre Study — an open, prospective, angiographically assessed trial in 51 patients with coronary heart disease and LDL cholesterol of 200 mg/dl or more despite diet and drug therapy — established the safety and tolerability of the procedure and documented its cholesterol-lowering effect over the first 12 months (Seidel et al., 1991). After two years of weekly treatment, pre-apheresis LDL had fallen from 286 to 205 mg/dl and fibrinogen from 314 to 250 mg/dl, and blinded angiography in 33 patients showed a small decrease in mean stenosis, with regression in 27% of segments and progression in 16% (Schuff-Werner et al., 1994). The study was not randomized and did not report a reduction in cardiovascular events. It has been used for over three decades in Germany for patients with familial hypercholesterolemia and elevated Lp(a) who do not achieve adequate control with statins.

Why it is relevant for post-COVID: The connection to post-COVID syndrome came through the microclot hypothesis. Etheresia Pretorius and colleagues reported that people with long COVID carry persistent fibrin amyloid microclots that resist normal fibrinolysis, together with raised antiplasmin levels and platelet hyperactivation; proteomic analysis of those microclots found entrapped pro-inflammatory molecules that may contribute to the failed fibrinolysis. H.E.L.P. Apheresis substantially lowers fibrinogen — the precursor of fibrin — and thereby reduces the substrate for microclot formation. On that basis, Jaeger, Seidel and colleagues (2022) argued from their clinical experience for H.E.L.P. in severe acute and chronic COVID-19. That paper is a mechanistic argument, not a trial, and two of its authors (Jaeger and Seidel) disclose having filed a patent on the use of H.E.L.P. apheresis for long COVID. A randomized trial of H.E.L.P. in long COVID has not been published, and Pretorius’s group itself calls for controlled studies before efficacy can be claimed.

How INUSpheresis Works

INUSpheresis was developed by INUS Medical GmbH as a therapeutic apheresis system with a broader filtration philosophy. Rather than targeting specific lipoproteins through chemical precipitation, INUSpheresis uses adsorption-based filters designed to capture a wider range of pathogenic substances.

The technical process:

1. Blood withdrawal: Similar to H.E.L.P. — blood is drawn and separated into plasma and cellular components.
2. Adsorption filtration: The plasma passes through a series of proprietary adsorption filters (the “INUS Filter” system). These filters contain binding media designed to attract and retain specific molecular classes through charge-based, hydrophobic, and affinity-based interactions.
3. Multi-target filtration: Unlike H.E.L.P.’s specific heparin-precipitation mechanism, INUSpheresis claims to filter multiple substance categories simultaneously — environmental toxins, heavy metals, inflammatory cytokines, autoantibodies, and what the manufacturer describes as “pathogenic proteins” including SARS-CoV-2 spike protein.
4. Plasma return: The filtered plasma is recombined with cellular components and returned to the patient.

What it claims to remove:

• Environmental toxins (pesticides, solvents, volatile organic compounds)
• Heavy metals (mercury, lead, cadmium; bound to plasma proteins)
• Inflammatory cytokines (TNF-alpha, IL-6, IL-1beta)
• Autoantibodies
• Histamine and other mast cell mediators
• Spike protein fragments (in the context of post-COVID or post-vaccination symptoms)
• Oxidized LDL and lipid peroxides

The evidence base:

This is where I must be direct: INUSpheresis has a substantially thinner evidence base compared to H.E.L.P. Apheresis. The published data consists primarily of case series and observational reports from INUS Medical-affiliated clinics. There are no published randomized controlled trials. The theoretical framework for broad-spectrum toxin removal is plausible, and the adsorption technology is scientifically sound, but the specific clinical claims exceed what the published evidence currently supports.

That said, practitioners using INUSpheresis do report improvement in some patients with chronic environmental toxin exposure, mast cell activation syndrome, and post-COVID symptoms. These are uncontrolled reports. Whether they reflect specific filtration effects, the non-specific effects of any plasma-processing procedure, or clinical attention cannot be determined without controlled trials, and I do not treat them as evidence of efficacy.

Head-to-Head Comparison

When I Recommend H.E.L.P. Apheresis

H.E.L.P. Apheresis is my preference when:

• Cardiovascular risk reduction is a primary goal: patients with elevated Lp(a), familial hypercholesterolemia refractory to statins, or high cardiovascular risk profiles. This is where H.E.L.P. has its strongest evidence and longest track record.
• Post-COVID with suspected microclotting: the fibrinogen reduction mechanism directly addresses the microclot hypothesis. Patients presenting with post-COVID fatigue, exercise intolerance, and elevated D-dimer or fibrinogen levels are logical candidates.
• Quantifiable targets: H.E.L.P. produces measurable, reproducible reductions in LDL, Lp(a), fibrinogen, and CRP. Pre- and post-session labs clearly demonstrate what has been removed. This measurability is clinically valuable for monitoring treatment response.
• Evidence-based practice is a priority: for patients or referring physicians who want the most evidence-supported option, H.E.L.P.’s 35-year track record and multiple published studies make it the more defensible choice.

What I tell my patients: if fibrinogen and lipoproteins are the primary targets, H.E.L.P. is the tool with the evidence behind it. It does one thing extremely well, and the data supports that.

When I Recommend INUSpheresis

INUSpheresis may be the better fit when:

• Environmental toxin burden is a primary concern: patients with documented heavy metal exposure, mold-related illness (CIRS), or chronic environmental toxin accumulation. H.E.L.P. was not designed for toxin removal; INUSpheresis claims this as a core function.
• Mast cell activation syndrome (MCAS): patients with histamine-related symptoms may benefit from the claimed removal of histamine and mast cell mediators. This is a plausible mechanism, though controlled data is lacking.
• Broad inflammatory load: patients with multi-system inflammation not primarily driven by lipoproteins or fibrinogen. The adsorption-based approach may capture a wider range of inflammatory mediators.
• Post-vaccination inflammatory syndromes: some practitioners report using INUSpheresis for patients with inflammatory symptoms following vaccination. The claimed spike protein removal is the theoretical basis, though this remains controversial and unvalidated by controlled studies.

Here is what the evidence shows: the theoretical framework for INUSpheresis is reasonable. Adsorption-based filtration can remove a broader range of substances than precipitation-based systems. But “can remove” and “has been demonstrated to remove in controlled conditions” are different statements, and the published evidence has not yet bridged that gap convincingly.

Can You Combine Them?

Some German clinics offer both systems and use them sequentially. The rationale for combining:

H.E.L.P. first: Remove the fibrinogen and lipoproteins that H.E.L.P. handles with well-documented efficiency. This addresses microclots, cardiovascular risk, and the acute inflammatory protein load.

INUSpheresis second: Follow with a broader-spectrum adsorption pass to target any remaining environmental toxins, cytokines, or other substances that H.E.L.P. does not specifically capture.

In practice, this combination approach is expensive (both in cost and in time) and is reserved for patients with complex, multi-factorial presentations — such as post-COVID patients who also have environmental toxin burden, or chronic Lyme patients with co-existing mold illness.

I want to be transparent: there are no published studies evaluating the combination approach versus either therapy alone. The rationale is mechanistic, and the clinical decision to combine is based on individual patient assessment rather than protocol-level evidence.

Clinical Perspective — Dr. med. univ. Julian Douwes

The apheresis landscape for post-COVID and chronic inflammatory conditions is evolving rapidly. H.E.L.P. Apheresis has the evidence base that makes it defensible to any physician or insurance reviewer — 35 years of cardiovascular data, reproducible outcomes, and measurable results. INUSpheresis addresses a different clinical need, targeting the broader toxin and inflammatory load that H.E.L.P. was not designed for. I do not view them as competitors. When a patient presents with elevated Lp(a), high fibrinogen, and post-COVID fatigue, I reach for H.E.L.P. When a patient presents with chronic environmental toxin exposure and multi-system inflammation, INUSpheresis may offer something that H.E.L.P. cannot. The honest position is that both have clinical utility, and the evidence base for one is substantially stronger than the other. Patients deserve to understand that distinction before making a treatment decision.

Key Takeaways

• H.E.L.P. Apheresis uses heparin-mediated precipitation to selectively remove LDL, Lp(a), fibrinogen, and CRP with 35+ years of evidence and multiple published studies.
• INUSpheresis uses adsorption-based filtration to target a broader range of substances including environmental toxins, cytokines, and inflammatory mediators, but has limited published clinical evidence.
• For post-COVID microclotting, H.E.L.P. has the stronger mechanistic and clinical rationale due to its potent fibrinogen reduction.
• For environmental toxin burden and broad detoxification, INUSpheresis addresses targets that H.E.L.P. was not designed for.
• Neither system is a standalone treatment: both are components of comprehensive treatment protocols.
• Combining both systems is practiced at some centers but lacks comparative evidence.
• Insurance coverage in Germany is available for H.E.L.P. for approved lipid indications but generally not for INUSpheresis.